AM-Pharma is developing a unique therapy against sepsis, based on detoxification of the bacterial endotoxin LPS. This is an early mediator in the sepsis cascade, and one of the highest possible upstream targets, and therefore a promising approach for the development of a successful therapy.
Dr. Bruno Giannetti, President & Chief Executive of AM-Pharma: "These are very promising data, although obtained in relatively small patient numbers, particularly when considering the fact that the dose and the treatment schedule still needs to be optimized. We are now in the process of planning a dose finding pivotal trial to optimize the dosing regime and demonstrate the efficacy of the drug."
A total of 36 patients admitted to intensive care units with the diagnosis of severe sepsis were included in the study (25 Verum/11 Placebo, 2:1 randomization scheme). The treatment consisted in a bolus of 67.5 U/ kg infused in the first 10 minutes followed by a 23 hour and 50 minutes infusion of a total of 132.5 U/kg.
The primary aim of the study was to assess safety of the treatment. Next to (serious) adverse events (S)AEs also 28 and 90 days survival rates were recorded.
The treatment was well tolerated. No drug-related SAEs were reported in the Verum group. The 28 days survival rates were 19/25 in the Verum and 7/11 in the Placebo group. The 90 days survival rates were 18/25 in the Verum and 6/11 in the Placebo group. The reduction of the mortality risk due to sepsis is represented by the calculated absolute and relative risk reduction. After 28 days, the Verum group showed 12.4% absolute risk reduction and 34% relative risk reduction. After 90 days absolute risk reduction was 17.5% and relative risk reduction was 38.4%.
More Information:
AM-Pharma is a clinical stage biopharmaceutical company based in Bunnik, the Netherlands. The company's business is focused on the preclinical and early clinical development of novel compounds in the field of severe infectious diseases and their consequences, as well as inflammatory diseases. AM-Pharma currently employs 22 staff and is financed by ABN-AMRO Capital Life Sciences and Inventages Venture Capital.
This release contains forward-looking statements that are not based on historical facts. These forward-looking statements involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on such forward-looking statements.
Source: AM-Pharma B.V.
